Pfizer Bets on Obesity and Cancer Drugs for Post-2028 Growth

Pharmaceutical giant Pfizer is focusing on new obesity and cancer drugs to accelerate growth from 2028 onward. The company expects its R&D efforts in these areas to support long-term revenue growth. In particular, candidate drugs developed for obesity treatment are anticipated to make a significant contribution with an expanding market share. While Pfizer's management faces declining revenues from COVID-19 products in the current period, it states that the new drug portfolio will offset this decline after 2028. Targeted therapies in oncology and obesity drugs are seen as the cornerstones of the company's growth strategy. In a highly competitive obesity drug market, the company aims to gain market share with differentiated products. Additionally, investments in immunotherapy and smart drug technologies for cancer treatment are planned to boost revenues in the post-2028 period. As Pfizer's strategy is closely monitored by investors, the impact of the company's R&D spending on profitability is also being assessed. Long-term growth expectations will be shaped by competition in the pharmaceutical sector and the outcomes of regulatory processes. This is not investment advice.